Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The Risk of "Extreme" Fasting: Longer fasts combined with GLP-1 therapy can lead to insufficient nutrient intake, which triggers muscle atrophy and a "yo-yo effect" once the medication is stopped
According to FDA labeling, the common side effects include: Gastrointestinal effects (with frequencies varying by dose): Nausea (12-30% of patients, often most prominent during dose escalation) Diarrhea (7-22%) Vomiting (2-10%) Constipation (5-17%) Abdominal pain or discomfort (5-10%) Decreased appetite (5-10%) Dyspepsia/indigestion (2-9%) Gastroesophageal reflux disease (1-5%, more common in weight management indication) Eructation/belching (more common in weight management indication) These gastrointestinal symptoms typically occur early in treatment or following dose increases and often diminish over time as the body adjusts to the medication
We hope that our 6+ years of working with the NHS and building a track record of effective weight-loss results will give you peace of mind to give us a try
Formulation (product) patent Covers a specific formulation or dosage form
Appetite control: Semaglutide reduces hunger signals by slowing gastric emptying, supporting lower calorie intake and sustained weight loss over time
